3D APT
MR Clinical applications
  • Product detail photograph
  • Product detail photograph
  • Product detail photograph
  • Product detail photograph
  • Product detail photograph
  • Standard product photograph

3D APT

MR Clinical applications
3D APT (Amide Proton Transfer)¹⁻³ is a unique, contrast-free, brain MR imaging method addressing the need for more confident diagnosis in neuro oncology. 3D APT uses the presence of endogenous cellular proteins, to produce an MR signal that directly correlates with cell proliferation, a marker of tumoral activity. 3D APT can support trained medical professionals in differentiating low grade from high grade gliomas and, in differentiating tumor progression from treatment effect⁴,⁵

Clinical image gallery

  • 3D APT
    3D APT
  • 3D APT
    3D APT
  • 3D APT
    3D APT
  • 3D APT
    3D APT
  • 3D APT
    3D APT

Documentation

Clinical applications brochure
PDF|10.98 MB
Datasheet 3D APT
PDF|189.91 KB

Related products

  • SmartPath MR system upgrade
    The smart approach to digital broadband MR- Ingenia owners enjoy enhanced image quality, advanced clinical capabilities, and efficient workflow from dStream broadband digital architecture. A SmartPath to dStream upgrade offers full dStream, without installing a completely new system.
  • Ingenia MR system
    We’ve designed Ingenia 3.0T CX with the performance that helps you explore with confidence, perform advanced clinical imaging that supports referrals, and conduct routine imaging efficiently. Thanks in part to exceptional Quasar Dual gradient performance. Your patients benefit from digital imaging that opens the door to personalized care.
  • Ingenia MR system
    At the forefront of clinical excellence - Diagnostic confidence, explore advanced applications, and generate the productivity required to meet today’s healthcare challenges with the Ingenia 3.0T. Through dStream, Ingenia delivers premium image quality with digital clarity and speed – and with iPatient¹, it provides patient-centric imaging, from patient set-up to image result.
Disclaimer
1 Zhou et al.,Nat Med 9, 1085-1090 (2003).
2 Zhou et al., Magn Reson Med 50, 1120-1126 (2003)
3 Jones et al., Magn Reson Med 56, 585-592 (2006).
4 Togao et al. (2014) Neuro-Oncology
5 Park KJ et al. (2016) Eur Radiol